NCT05230745 is a NA clinical trial of ContraBand implants in Heart Failure, Left Sided, sponsored by Restore Medical Ltd.

Who is sponsoring NCT05230745?

NCT05230745 is sponsored by Restore Medical Ltd.

What drugs are being tested in NCT05230745?

Interventions in NCT05230745: ContraBand implants.

What condition does NCT05230745 study?

NCT05230745 studies Heart Failure, Left Sided.

Is NCT05230745 still recruiting?

NCT05230745 is currently recruiting now. Last updated 5 February 2026.

Last reviewed 2026-02-05 · How we verify

NCT05230745

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ContraBand™: Safety & Feasibility Study (RM-20-01)

Recruiting now NA Last updated 5 February 2026

What this trial tests

NA trial testing ContraBand implants in Heart Failure, Left Sided in 55 participants. Currently enrolling.

Timeline

28 September 2021

Primary endpoint
30 June 2029

31 December 2032

Quick facts

Lead sponsor	Restore Medical Ltd
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	55
Start date	28 September 2021
Primary completion	30 June 2029
Estimated completion	31 December 2032
Sites	12 locations across Georgia, Belgium, Israel, Germany, Poland, Lithuania

Drugs / interventions tested

ContraBand implants

Conditions studied

Heart Failure, Left Sided — all drugs for Heart Failure, Left Sided →

Sponsor

Restore Medical Ltd

Who can join

Adults 18 to 85, any sex, with Heart Failure, Left Sided. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ContraBand™ is a transcatheter constriction device which is implanted in the left and right branch pulmonary arteries. The effect is achieved by causing a local reduction in the internal diameters of the branch PAs, resulting in a lower distal systolic pulmonary artery pressure (PAP) as well as an attenuation in the rise of the mean pulmonary capillary wedge pressure (PCWP) along with a higher pulmonary arterial compliance (PAC) distal to the constriction during exercise. Lower PCWP reflects the reduced left ventricular end diastolic pressure (LVEDP), contributing to enhanced ventricular filling and improved cardiac output. This hemodynamic change is anticipated to translate into enhanced physical capacity and a potentially more favorable prognosis for heart failure subjects. This study is an early feasibility, multi center, prospective, interventional, open-label, single-arm study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Transcatheter Pulmonary Artery Banding for HFrEF: Initial Results: Exercise Hemodynamics From the Ongoing First-in-Human Trial.
Bruckheimer E, Rackauskas G, Verheye S, Prihadi E, et al · · 2024 · cited 6× · PMID 38680953 · DOI 10.1016/j.jacbts.2024.02.008

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05230745 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Restore Medical Ltd
Last refreshed: 5 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05230745.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing